The HIF-2? inhibitor casdatifan demonstrated positive efficacy in the treatment of patients with late-line metastatic clear cell renal cell carcinoma across all monotherapy cohorts in the phase 1/1b ARC-20 trial (NCT05536141), according to a press re... [4930 chars].. reed more
